Abstract | BACKGROUND: PATIENTS AND METHODS: Previously treated NSCLC patients were randomly allocated (1:1) to receive docetaxel (60 mg/m²) on day 1 or nab-paclitaxel (100 mg/m²) on days 1, 8, and 15 of a 21-day cycle. Safety and efficacy outcomes of treatment were evaluated according to renal function. RESULTS: CONCLUSION:
Nab-paclitaxel was found to be tolerable and beneficial for previously treated patients with advanced NSCLC and mild or moderate renal impairment.
|
Authors | Yasuto Yoneshima, Satoshi Morita, Masahiko Ando, Atsushi Nakamura, Shunichiro Iwasawa, Hiroshige Yoshioka, Yasuhiro Goto, Masafumi Takeshita, Toshiyuki Harada, Katsuya Hirano, Tetsuya Oguri, Masashi Kondo, Satoru Miura, Yukio Hosomi, Terufumi Kato, Toshio Kubo, Junji Kishimoto, Nobuyuki Yamamoto, Yoichi Nakanishi, Isamu Okamoto |
Journal | Clinical lung cancer
(Clin Lung Cancer)
Vol. 23
Issue 7
Pg. 585-592
(11 2022)
ISSN: 1938-0690 [Electronic] United States |
PMID | 36114096
(Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2022. Published by Elsevier Inc. |
Chemical References |
- 130-nm albumin-bound paclitaxel
- Creatinine
- Docetaxel
|
Topics |
- Humans
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, etiology)
- Creatinine
(therapeutic use)
- Docetaxel
(therapeutic use)
- Lung Neoplasms
(drug therapy, etiology)
|